Best Viral Vector CDMOs in United States
· updated as new inspection, certificate, and trial data enters the platform
41
CDMOs tracked
34
Fully scored
15
With FDA records
38
FDA inspections
103
EMA/MHRA GMP certs
For US-manufactured viral vector programs, Thermo Fisher Scientific, AGC Biologics, and Takeda lead CDMO Signal's ranking of viral vector CDMOs with confirmed US facilities. Filtered from the global directory of 60 scored viral vector CDMOs to 5 with US manufacturing presence. US-based manufacturing carries specific advantages for sponsors filing under FDA jurisdiction: FDA inspection records — which form the core of the Signal Score's Quality Compliance pillar — apply directly, and QP release complexity common to EU-manufactured material does not apply. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.
Viral vector CDMOs manufacture the three GMP-relevant vector platforms used in modern gene therapy and gene-modified cell therapy: adeno-associated virus (AAV), lentivirus, and adenovirus. Each platform has distinct process, containment, and analytics requirements, and CDMOs typically specialize in one or two platforms rather than all three. Platform is the first shortlist filter in any viral vector procurement decision.
This ranking aggregates every CDMO tracked as a viral vector manufacturer across the three platforms. For platform-specific rankings with process-critical detail (BSL-2 containment for lentivirus, full/empty capsid analytics for AAV, high-titre transient expression for adenovirus), use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors integrating vector supply with downstream cell processing (CAR-T, gene-modified HSC), the <a href="/modality/cell-and-gene-therapy">cell & gene therapy view</a> extends this list with cell therapy CDMOs.
FDA inspection outcomes across these CDMOs: 17 NAI (no action), 21 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (35), United States (34), UNITED KINGDOM (23), Austria (9), Ireland (9).
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
83.1 | 97.9 | 6 insp · 10 GMP | Available | 2 programs |
| 2 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 3 |
TK
Takeda
Boston, MA · Zurich, CH
|
80.5 | 99.3 | 4 insp · 18 GMP | — | 100 programs |
| 4 |
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
|
75.2 | 100.0 | 1 insp · 0 GMP | — | 1 programs |
| 5 |
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
|
73.4 | 97.7 | 1 insp · 0 GMP | Available | 9 programs |
| 6 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 7 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 8 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
85.6 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 9 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
83.7 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 10 |
KB
KBI Biopharma
Durham, NC · Boulder, CO
|
83.5 | 100.0 | 1 insp · 1 GMP | Limited | 0 programs |
| 11 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
83.5 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 12 |
DH
Danaher (CGT Portfolio)
Washington, DC
|
81.5 | — | — | — | 0 programs |
| 13 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
81.0 | 98.8 | 4 insp · 8 GMP | — | 0 programs |
| 14 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 15 |
BB
bluebird bio Manufacturing
Durham, NC
|
78.5 | — | — | — | 0 programs |
| 16 |
AG2
August Bioservices
San Carlos, CA
|
77.4 | 98.5 | 1 insp · 0 GMP | — | 0 programs |
| 17 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
75.1 | 79.3 | 1 insp · 0 GMP | Available | 0 programs |
| 18 |
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
|
74.0 | — | — | — | 0 programs |
| 19 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| 20 |
VE
Vigene Biosciences
Rockville, MD
|
72.5 | — | — | — | 0 programs |
| 21 |
EM
Emergent BioSolutions (CGT)
Baltimore, MD
|
71.0 | — | — | — | 4 programs |
| 22 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
70.7 | 84.1 | 3 insp · 0 GMP | Available | 0 programs |
| 23 |
AN
Andelyn Biosciences
Columbus, OH
|
63.0 | — | — | Available | 0 programs |
| 24 |
UM
MassBiologics
Boston, MA
|
63.0 | — | 1 insp · 0 GMP | — | 0 programs |
| 25 |
FB
Forge Biologics
Columbus, OH
|
62.7 | — | — | 3 programs | |
| 26 |
MS
Made Scientific
Princeton, NJ
|
61.5 | — | — | — | 0 programs |
| 27 |
GF
GeneFab
Alameda, CA and South San Francisco
|
61.5 | — | — | Available | 0 programs |
| 28 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
60.5 | — | — | — | 0 programs |
| 29 |
AB
Asklepios BioPharmaceutical (AskBio)
Research Triangle, NC · San Sebastian, ES
|
59.7 | — | — | — | 10 programs |
| 30 |
MA
Matica Biotechnology
College Station, TX
|
59.0 | — | — | Available | 0 programs |
| 31 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 32 |
WB
Waisman Biomanufacturing
Madison, WI
|
59.0 | — | — | — | 0 programs |
| 33 |
EB
ElevateBio BaseCamp
Waltham, MA
|
59.0 | — | — | — | 0 programs |
| 34 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| — |
Rose BioSolutions
Wilmington, MA
|
Profiled | — | — | — | 0 programs |
| — |
Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
|
Profiled | — | — | — | 0 programs |
| — |
Porton Advanced
Cranbury, NJ
|
Profiled | — | — | — | 0 programs |
| — |
Vantage Vector (Demo)
Gaithersburg, MD
|
Profiled | — | — | Available | 0 programs |
| — |
Advanced BioScience Laboratories, Inc. (ABL Inc.)
Rockville, MD
|
Profiled | — | — | — | 0 programs |
| — |
Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)
Novato, CA
|
Profiled | — | — | — | 0 programs |
| — |
Landmark Bio
Watertown, MA
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Viral Vector CDMO
Vector platform match
First shortlist filter for any viral vector program is platform. AAV for in vivo systemic, lentiviral for ex vivo cell engineering, adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within.
Facility-level regulatory record on the platform
A CDMO's strong FDA record on AAV does not automatically de-risk their lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use, not the CDMO's aggregate score.
Analytics maturity per vector
Full/empty capsid separation for AAV, RCL testing for lentivirus, particle-to-infectivity ratio for adenovirus — each platform has non-negotiable release-testing requirements. A CDMO's qualified, validated assay panel for the specific vector is the single most under-appreciated cost driver in viral vector programs.
Capacity match to phase and dose
AAV early clinical runs at 50-200L, commercial at 1,000-2,000L single batch; lentiviral commercial supply is a narrower field with per-patient-dose economics. Confirm the CDMO's capacity headroom at your target phase before shortlisting — capacity constraints appear late and derail commercial launches.
FDA jurisdiction — how the ranking scores US-based CDMOs
The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.
Which US CDMOs also cover EU and UK regulatory geographies?
Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.
How CDMO Signal identifies US manufacturing presence
Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.
Viral Vector CDMOs — Frequently Asked Questions
Who are the top Viral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Viral Vector CDMOs include Thermo Fisher Scientific, AGC Biologics, Takeda. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Viral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 15 Viral Vector CDMOs with FDA inspection records and 103 EMA/MHRA GMP certificates across the group.
What should I look for in a viral vector CDMO?
Match the vector platform first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, vector-specific analytics maturity, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific technical detail worth reading before finalizing a shortlist.
How many viral vector CDMOs does CDMO Signal track?
65+ CDMOs are tracked across the three GMP viral vector platforms — the union of AAV, lentiviral, and adenoviral manufacturers, deduplicated. Each is scored independently on the standard four-pillar Signal Score composite.
How is viral vector manufacturing different from mAb or recombinant protein biologics?
Viral vector manufacturing shares the mammalian cell culture upstream backbone with biologics but diverges sharply on downstream. Viral vector downstream requires enveloped/non-enveloped virus purification (chromatography, tangential flow filtration, ultracentrifugation) rather than protein A affinity capture. Analytics differ fundamentally — infectious titer and capsid analytics for viral vectors vs product-related impurities for biologics. Regulatory paths also differ: viral vectors carry additional biosafety review (RCL for lentivirus, adventitious agents for all platforms) beyond standard biologics.
Related modalities